Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate

Zachary J. Arnold, Jordan Lundberg, Tracy Wiczer, Demond Handley, David Bond, Yazeed Sawalha, Audrey Sigmund, John Reneau, Walter Hanel, John Sharp, Youssef Youssef, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Kami Maddocks, Narendranath Epperla, Timothy J. Voorhees

Journal of Oncology Pharmacy Practice

Published online on February 04, 2026

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionHigh-dose systemic methotrexate (HD-MTX) in doses ≥ 3 g/m2is the cornerstone of treatment for central nervous system (CNS) lymphomas and prophylaxis for patients with high-risk of CNS relapse. Its administration requires extensive supportive ...